1. Bradner WT, Rose WC, Huftalen JB (1980) Antitumor activity of platinum analogs. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin. Current status and new developments. Academic, New York, p 171
2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TU, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140
3. Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM (1983) A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res 43: 4470
4. Egorin MJ, VanEcho DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutane-dicarboxylato)platinum in patients with impaired renal function. Cancer Res 44: 5432
5. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984a) Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (CBDCA, JM8) in patients with normal and abnormal renal function. In: Hacker MP, Douple EB, Krakoff IH (eds) Platinum coordination complexes in cancer chemotherapy. Nijhoff, Boston, p 146